CanakinumabCanakinumab
MedChemExpress (MCE)
HY-108810
914613-48-2
Ilaris
ACZ 885
99.64%
Please store the product under the recommended conditions in the Certificate of Analysis.
Shipping with dry ice.
Canakinumab (ACZ885) is a recombinant human anti-IL-1β monoclonal antibody. Canakinumab shows IC50 values of 43.6 and 40.8 pM for human and marmoset IL-1β, respectively. The mode of action of canakinumab is based on the neutralization of IL-1β signaling, resulting in suppression of inflammation related to disorders of autoimmune origin.
Canakinumab (0-7 nM) dose dependently represses IL-6 production in marmoset peripheral blood mononuclear cells with IC50s of 43.6 and 40.8 pM for human and marmoset IL-1β[2]. Canakinumab effectively competes with IL-1RI and IL-1RII for binding to IL-1b[2].
IC50: 43.6 pM (human IL-1β), 40.8 pM (marmoset IL-1β)[2] In Vitro Canakinumab (0-7 nM) dose dependently represses IL-6 production in marmoset peripheral blood mononuclear cells with IC50s of 43.6 and 40.8 pM for human and marmoset IL-1β[2]. Canakinumab effectively competes with IL-1RI and IL-1RII for binding to IL-1b[2]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> Canakinumab Related Antibodies
Human
Human IgG1(K214R) kappa
Human IgG1 (K214R) kappa, Isotype Control
| | | |
| | | | | |
[1]. Dhimolea E. Canakinumab. MAbs. Epub 2010 Jan 15. [Content Brief]
[2]. Rondeau JM, et al. The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1β. MAbs. 2015
7(6):1151-60. [Content Brief]